Course Content
🫁 Theme I — Pain and Fatigue
🫁 Theme II — Trauma and Repair
Infection & Inflammation (Foundation II) Module — 3rd Year MBBS
AIM Concept Integration
3rd Year MBBS
Infection and Inflammation

Topic 22 — Fungal Infections and Antifungal Pharmacotherapy

Connect Aspergillus and Candida with their disease patterns, diagnostic clues and the major antifungal drug targets for rapid revision.

1. THE TOPIC IN ONE CONNECTED FLOW

Fungal disease depends on both the organism and the host. Aspergillus is mainly encountered as an inhaled environmental mould, whereas Candida may already colonize mucosal surfaces. Disease develops when the fungus produces an allergic response, colonizes an abnormal site or invades tissue. Antifungal drugs then act mainly by damaging fungal membrane ergosterol, blocking its synthesis or interfering with fungal growth.

Organism / Exposure
Aspergillus: inhaled conidia
Candida: mucosal colonizer
→
Host / Local Change
Immune impairment, abnormal cavity or loss of microbial balance
→
Fungal Behaviour
Allergy, colonization or tissue invasion
→
Clinical Effect
Pulmonary disease, hemoptysis, mucosal candidiasis or invasive infection
→
Diagnostic Clue
Hyphal or yeast morphology, microscopy, histology and culture
→
Antifungal Target
Ergosterol, sterol synthesis or fungal microtubules
Drug connection:

Amphotericin B / nystatin → bind ergosterol → membrane leakage;
azoles → inhibit 14-alpha-demethylase → reduced ergosterol;
terbinafine → inhibits squalene epoxidase → reduced ergosterol + squalene accumulation;
griseofulvin → disrupts fungal microtubules → impaired mitosis.

2. KEY CLINICAL CONNECTIONS

Aspergillus disease pattern

Inhaled conidia
→
septate acute-angle branching hyphae
→
cavity colonization or invasive growth
→
hemoptysis or tissue necrosis.

Vascular invasion
→
thrombosis
→
ischemia, hemorrhage and necrosis.

Candida opportunism

Normal mucosal colonization
→
disturbed flora or weakened barriers
→
overgrowth
→
pseudohyphal / hyphal invasion
→
candidiasis.

Budding yeast + pseudohyphae
→
supports laboratory recognition when matched with the clinical site.

Antifungal efficacy versus toxicity

Amphotericin B
→
ergosterol binding
→
fungal membrane pores
→
strong systemic antifungal effect
→
nephrotoxicity and infusion reactions.

Liposomal formulation
→
altered tissue distribution
→
lower renal exposure
→
reduced nephrotoxicity.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Aspergillus morphology → diagnosis:
septate hyphae with acute-angle branching strongly support Aspergillus when seen in the appropriate clinical specimen.
⭐ Angioinvasion → complication:
hyphal invasion of vessels causes thrombosis and reduced blood supply, explaining hemorrhagic infarction and tissue necrosis.
Pre-existing cavity → aspergilloma:
fungal colonization forms an intracavitary mass and may produce hemoptysis without the widespread tissue invasion seen in invasive disease.
Candida colonization → disease:
disruption of normal flora or epithelial defence permits overgrowth, while budding yeast and pseudohyphae provide useful diagnostic morphology.
⭐ Polyenes → membrane injury:
amphotericin B and nystatin bind ergosterol; amphotericin B is used for severe systemic infection, whereas nystatin is mainly used locally.
⭐ Azoles versus terbinafine:
both reduce ergosterol, but azoles inhibit 14-alpha-demethylase while terbinafine inhibits squalene epoxidase and causes squalene accumulation.
Ketoconazole → PK and interactions:
acidic gastric conditions support absorption, hepatic metabolism is important, and CYP inhibition explains significant drug interactions.
Griseofulvin → keratin + mitosis:
deposition in newly formed keratin limits dermatophyte invasion, while disruption of fungal microtubules inhibits cell division.
AIM Exam Trap:

Amphotericin B and nystatin bind existing ergosterol; azoles and terbinafine inhibit ergosterol synthesis; griseofulvin acts on fungal microtubules.
Scroll to Top
💬 WhatsApp Support